Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 6;13:901437. doi: 10.3389/fimmu.2022.901437

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Iwasaki, Watanabe, Ito, Fujii, Okuma, Oku, Hirayama, Ohmura, Murata, Murakami, Yoshitomi, Tanaka, Matsuda, Matsuda, Morinobu and Hashimoto

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Relationships between the IFN signature and other phenotypes and an evaluation of their clinical utility as predictive markers. (A–C) Relationships between IFN scores and other phenotypes. Each dot represents each specimen. Blue represents responders before treatment, orange for non-responders before treatment, green for responders three months after treatment, and red for non-responders three months after treatment. (D, E) Relationships between treatment responses and the number of lymphocytes and CXCL10 levels. Fifty-four specimens (27 samples × 2 timepoints) were analyzed. (F) Relationship between HGF levels before treatment and treatment responses. (G–I) ROC curves for no response to TNFi. Red plots indicate the cut-off points at the highest accuracy (minimum false negative and false positive results) for predicting non-responders.